small molecules
| 2 min read
The new Carterra Vega HT-SPR system combines 48 parallel channels with high-resolution binding data, enabling primary screening at a scale previously unattainable with label-free technologies.
| 4 min read
By reengineering small-molecule chemistry for automation, Excelsior aims to remove a long-standing barrier to AI-driven drug discovery.
| 4 min read
Early clinical trials show that a KRAS G12D inhibitor can shrink tumors in patients with advanced pancreatic and other solid cancers.
| 3 min read
How a team at Pfizer turned a decade-old compound into the fastest small molecule drug for COVID-19.
| 2 min read
A new class of small-molecule drugs could represent a therapeutic modality aimed at eliminating disease-causing proteins before they spread in the body.
| 2 min read
A disease once synonymous with a shortened lifespan is now a model for how drug discovery can directly alter the natural history of genetic disorders.
| 4 min read
Live-cell kinetic assays provide time-resolved insights into degrader pharmacology, supporting both lead prioritization and translational modeling.
| 4 min read
A new platform may finally unlock the rules behind molecular glue degraders, turning chance discoveries into programmable therapeutics.
| 3 min read
The deal reflects growing interest in covalent chemistry as a solution for “undruggable” inflammatory proteins.
| 2 min read
EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema.
